Gliclazide improves anti‐oxidant status and nitric oxide‐mediated vasodilation in Type 2 diabetes

Abstract

Abstract Aims To evaluate the effects of gliclazide on oxidative status and vascular response to systemic administration of L‐arginine, the natural precursor of nitric oxide (NO), in Type 2 diabetic patients. Methods Thirty Type 2 diabetic patients received glibenclamide ( n = 15) or gliclazide ( n = 15) in a 12‐week, randomized, observer‐blinded, parallel study. Plasma lipid peroxides, total radical‐trapping anti‐oxidant parameter (TRAP), and blood pressure responses to an intravenous bolus of L‐arginine were measured pre‐ and post‐treatment. Results At 12 weeks, gliclazide patients had lower plasma lipid peroxides (13.3 ± 3.8 µmol/l vs. 19.2 ± 4.3 µmol/l; P = 0.0001) and higher plasma TRAP (1155.6 ± 143.0 µmol/l vs. 957.7 ± 104.3 µmol/l; P = 0.0001) than the glibenclamide patients. Gliclazide but not glibenclamide significantly reduced systolic and diastolic blood pressure ( P = 0.0199 and P = 0.00199, respectively, two‐way repeated measures analysis of variance) in response to intravenous L‐arginine. Conclusions Gliclazide reduces oxidative stress in Type 2 diabetic patients by improving plasma anti‐oxidant status. This effect is associated with enhanced NO‐mediated vasodilation.

Keywords

Affiliated Institutions

• Sapienza University of Rome IT

Related Publications